Alnylam partners with GSK over 'stealth' RNAi vaccine manufacturing technology
This article was originally published in Scrip
Executive Summary
Alnylam Pharmaceuticals has formed a collaboration deal with GlaxoSmithKline centred around an RNAi technology called VaxiRNA that Alnylam has been developing to enhance vaccine production. "We purposely kept this effort stealthy over the last couple of years to advance our data and our IP estate," CEO John Maraganore said during a conference call on 1 November.